Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dixanthogen SCHEMBL37053 | 0.88 | ALDH1A1 (0.50) | ALDH1A1CYP2D6CA12CA1CA2 | |
| Dixanthogen SCHEMBL1415905 | 0.86 | ALDH1A1 (0.48) | ALDH1A1CYP2D6CA12CA1CA2 | |
| Dixanthogen SCHEMBL11408546 | 0.86 | ALDH1A1 (0.48) | ALDH1A1CYP2D6CA12CA1CA2 | |
| Dixanthogen SCHEMBL7105038 | 0.83 | ALDH1A1 (0.46) | ALDH1A1CYP2D6CA12CA1CA2 | |
| SCHEMBL11684235 | 0.82 | ALDH1A1 (0.38) | ALDH1A1CYP2D6CA12CA1CA2 | |
| SCHEMBL11830672 | 0.79 | ALDH1A1 (0.43) | ALDH1A1CYP2D6CA12CA1CA2 | |
| SCHEMBL11822867 | 0.79 | ALDH1A1 (0.43) | ALDH1A1CYP2D6CA12CA1CA2 | |
| SCHEMBL11685818 | 0.79 | ALDH1A1 (0.36) | ALDH1A1CYP2D6CA12CA1CA2 | |
| Dixanthogen SCHEMBL9840346 | 0.77 | ALDH1A1 (0.47) | ALDH1A1CYP2D6CA12CA1CA2 | |
| SCHEMBL30901364 | 0.77 | ALDH1A1 (0.38) | ALDH1A1CYP2D6CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6809195-B1 | COMPRISES A MODIFIED PHOSPHORAMIDITE PROTOCOL IN WHICH OXIDATION AND CAPPING STEPS ARE COMBINED INTO A SINGLE STEP; INCREASED EFFICIENCY; SOLID PHASE SYNTHESIS | ISIS PHARMACEUTICALS, INC. | 2004-10-26 | — | — | US | disclosed |
| US-20040198972-A1 | Processes for the preparation of oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2004-10-07 | — | — | US | disclosed |
| US-6762281-B2 | GENERATING PREFERENTIAL OLIGOMERS; GENERATE OLIGOMER, DEPROTECT, EXPOSE TO PHOSPHOROUS, OXIDIZE, EXPOSE TO SULFUR, CLEAVE, RECOVER PRODUCT | ISIS PHARMACEUTICALS, INC. | 2004-07-13 | — | — | US | disclosed |
| US-6559279-B1 | Generation of peptide linked oligomers; generate solid support, expose to deprotecting agent, incubate with nucleoside, cap, cleave and recover peptide derivative | ISIS PHARMACEUTICALS, INC. | 2003-05-06 | — | — | US | disclosed |
| US-20020156235-A1 | Process for preparing peptide derivatized oligomeric compounds | IONIS PHARMACEUTICALS, INC. | 2002-10-24 | — | — | US | disclosed |
| US-6384209-B1 | HIGHLY EFFIENT PROCESS BY CONTACTING OLIGONUCLEOTIDE HAVING INTERNUCLEOSIDE LINKAGE OF A PHOSPHOROUS III ATOM WITH A REAGENT OF DEFINED STRUCTURE; REAGENTS ARE INEXPENSIVE TO MAKE AND STABLE IN STORAGE | AVECIA BIOTECHNOLOGY, INC. (GB) | 2002-05-07 | — | — | US | disclosed |
| WO-2002020544-A1 | PROCESS FOR PREPARING PEPTIDE DERIVATIZED OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-1998008809-A1 | NOVEL SULFUR TRANSFER REAGENTS FOR OLIGONUCLEOTIDE SYNTHESIS | HYBRIDON, INC. (US) | 1998-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156235-A1 | Process for preparing peptide derivatized oligomeric compounds | IAPP, PTMS, NGLY1 | ALDH1A1 4879/4885CYP2D6 4877/4885CA12 1771/4885 |
| US-20040198972-A1 | Processes for the preparation of oligonucleotides | RNGTT, RNMT, NUDT1 | ALDH1A1 3915/4885CYP2D6 3939/4885CA12 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.